TD Cowen Issues Positive Forecast for Revvity (NYSE:RVTY) Stock Price

Revvity (NYSE:RVTY) had its price objective upped by TD Cowen from $175.00 to $185.00 in a research report report published on Wednesday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

RVTY has been the topic of several other research reports. Royal Bank Of Canada increased their target price on Revvity from $135.00 to $172.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Finally, Evercore reaffirmed an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, Revvity has a consensus rating of “Hold” and an average price target of $133.86.

Revvity Trading Down 2.3%

Shares of Revvity stock opened at $159.68 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.65 and a quick ratio of 1.50. The stock’s 50 day simple moving average is $146.58 and its 200-day simple moving average is $112.84. The stock has a market cap of $17.82 billion, a P/E ratio of 29.46, a P/E/G ratio of 2.95 and a beta of 1.08. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.30 by $0.08. The firm had revenue of $728.90 million during the quarter, compared to analysts’ expectations of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Analysts predict that Revvity will post 5.41 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, January 22nd. Revvity’s dividend payout ratio is presently 13.33%.

Insider Activity at Revvity

In related news, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of Revvity stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This represents a 52.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Revvity

Several institutional investors have recently modified their holdings of RVTY. Pillar Financial Advisors LLC acquired a new position in shares of Revvity during the third quarter worth $29,000. Heritage Family Offices LLP acquired a new stake in Revvity in the third quarter valued at $37,000. Ascentis Independent Advisors acquired a new stake in Revvity in the first quarter valued at $29,000. Root Financial Partners LLC purchased a new stake in Revvity during the 3rd quarter worth about $64,000. Finally, Global Retirement Partners LLC purchased a new stake in Revvity during the 2nd quarter worth about $51,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity beat third-quarter estimates, reporting adjusted EPS of $1.38 versus a $1.30 consensus and revenue of $728.9 million versus $694.7 million. Revenue increased 4.3% year over year, with Life Sciences strength and margin expansion cited, and the company raised its 2026 outlook. Q3 earnings and outlook
• Positive Sentiment: CFRA upgraded the stock from Hold to Buy. TD Cowen also raised its price target to $185 and maintained a Buy rating, signaling further potential upside. TD Cowen price-target change
• Neutral Sentiment: Other analysts raised targets but kept more cautious ratings: Barclays set $175 with Equal Weight, RBC set $172 with Sector Perform, and JPMorgan set $160 with Neutral. The range of views suggests analysts see improvement, but not uniform conviction. JPMorgan price-target change
• Negative Sentiment: Valuation may temper enthusiasm: coverage questioned whether the stock is now too expensive, while JPMorgan’s new target is close to the referenced share price. This could contribute to a pullback even after the earnings beat. Valuation and dividend coverage

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.